login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock News
USA
-
Nasdaq
- NASDAQ:ARCT -
US03969T1097
-
Common Stock
6.25
USD
-0.24 (-3.7%)
Last: 12/2/2025, 8:27:12 PM
6.2546
USD
+0 (+0.07%)
After Hours:
12/2/2025, 8:27:12 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ARCT Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Zacks Investment Research
- Mentions:
CRMD
ADMA
ARQT
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
8 days ago - By: Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics to Attend Upcoming Investor Conference
22 days ago - By: Zacks Investment Research
- Mentions:
TCRX
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
22 days ago - By: Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
26 days ago - By: Benzinga
Preview: Arcturus Therapeutics's Earnings
a month ago - By: Benzinga
Where Arcturus Therapeutics Stands With Analysts
23 days ago - By: Edelson Lechtzin LLP
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
a month ago - By: Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics to Attend Upcoming Investor Conferences
a month ago - By: Zacks Investment Research
- Mentions:
FATE
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
a month ago - By: Zacks Investment Research
- Mentions:
IOVA
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
3 months ago - By: Zacks Investment Research
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?
a month ago - By: Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
a month ago - By: The Motley Fool
- Mentions:
HOOD
NFLX
Cathie Wood Goes Shopping: 3 Stocks She Just Bought
a month ago - By: Stocktwits
- Mentions:
VFMO
IWMW
Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off?
a month ago - By: Investor's Business Daily
Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug
a month ago - By: Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
Please enable JavaScript to continue using this application.